Infectious mononucleosis and Epstein-Barr virus.

Area of Science:

• Virology
• Immunology
• Infectious Diseases

Background:

• Epstein-Barr virus (EBV), a common gamma-herpesvirus, infects over 90% of the global population.
• EBV establishes lifelong latent infections in B cells and oropharyngeal cells following transmission via saliva.
• Primary EBV infection is typically asymptomatic in childhood but can cause infectious mononucleosis (mono) in adolescents and adults.

Purpose of the Study:

• To review primary Epstein-Barr virus infection in individuals with infectious mononucleosis.
• To elucidate EBV's infection establishment mechanisms and the host's primary immune response.
• To summarize research toward an EBV vaccine for preventing infectious mononucleosis.

Main Methods:

• Review of existing literature on Epstein-Barr virus primary infection.
• Analysis of EBV pathogenesis, including viral entry and immune evasion strategies.
• Summary of clinical manifestations of infectious mononucleosis.
• Overview of current vaccine development efforts against EBV.

Main Results:

• EBV establishes infection through oropharyngeal and B-cell pathways.
• Primary infection elicits a specific immune response, often leading to infectious mononucleosis symptoms like fever, pharyngitis, and lymphadenopathy.
• A subset of EBV-infected individuals develop associated malignancies.

Conclusions:

• Understanding EBV's infection dynamics is crucial for managing infectious mononucleosis.
• Ongoing research focuses on developing a preventative vaccine for EBV-associated infectious mononucleosis.
• Further studies are needed to fully comprehend EBV's oncogenic potential.